View Item 

Show simple item record

Epidemiology and management of uterine fibroids
dc.contributor.authorGiuliani, Emma
dc.contributor.authorAs‐sanie, Sawsan
dc.contributor.authorMarsh, Erica E.
dc.date.accessioned2020-03-17T18:35:15Z
dc.date.availableWITHHELD_14_MONTHS
dc.date.available2020-03-17T18:35:15Z
dc.date.issued2020-04
dc.identifier.citationGiuliani, Emma; As‐sanie, Sawsan ; Marsh, Erica E. (2020). "Epidemiology and management of uterine fibroids." International Journal of Gynecology & Obstetrics 149(1): 3-9.
dc.identifier.issn0020-7292
dc.identifier.issn1879-3479
dc.identifier.urihttps://hdl.handle.net/2027.42/154526
dc.description.abstractUterine leiomyomas are one of the most common and yet understudied diseases in women. These tumors, commonly known as fibroids, affect women mainly during their reproductive years and are diagnosed in up to 70% of white women and more than 80% of women of African ancestry during their lifetime. This disease has a profound impact on health care delivery and costs worldwide. Though most women with fibroids are asymptomatic, approximately 30% of them will present with severe symptoms which can include abnormal uterine bleeding, anemia, pelvic pain and pressure, back pain, urinary frequency, constipation, or infertility, and will require intervention. Furthermore, fibroids have been associated with poor obstetrical outcomes. The current options for symptomatic fibroid treatment include expectant, medical, and surgical management, and interventional radiology procedures. This article reviews the recent progress and available management strategies for uterine fibroids and highlights areas where further research is needed to find new therapeutic targets and better personalize treatments.We provide a review of the management options for uterine fibroids.
dc.publisherWiley Periodicals, Inc.
dc.subject.otherLeiomyomas
dc.subject.otherUterine fibroids
dc.subject.otherAbnormal uterine bleeding
dc.titleEpidemiology and management of uterine fibroids
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelObstetrics and Gynecology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/154526/1/ijgo13102.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/154526/2/ijgo13102_am.pdf
dc.identifier.doi10.1002/ijgo.13102
dc.identifier.sourceInternational Journal of Gynecology & Obstetrics
dc.identifier.citedreferenceIshikawa H, Reierstad S, Demura M, et al. High aromatase expression in uterine leiomyoma tissues of African American women. J Clin Endocrinol Metab. 2009; 94: 1752 â 1756.
dc.identifier.citedreferenceStewart EA, Cookson CL, Gandolfo RA, Schulzeâ Rath R. Epidemiology of uterine fibroids: A systematic review. BJOG. 2017; 124: 1501 â 1512.
dc.identifier.citedreferenceLethaby A, Duckitt K, Farquhar C. Nonâ steroidal antiâ inflammatory drugs for heavy menstrual bleeding. Cochrane Database Syst Rev. 2013;( 1 ): CD000400.
dc.identifier.citedreferenceLukes AS, Moore KA, Muse KN, et al. Tranexamic acid treatment for heavy menstrual bleeding: A randomized controlled trial. Obstet Gynecol. 2010; 116: 865 â 875.
dc.identifier.citedreferenceMoroni RM, Martins WP, Dias SV, et al. Combined oral contraceptive for treatment of women with uterine fibroids and abnormal uterine bleeding: A systematic review. Gynecol Obstet Invest. 2015; 79: 145 â 152.
dc.identifier.citedreferenceJiang W, Shen Q, Chen M, et al. Levonorgestrelâ releasing intrauterine system use in premenopausal women with symptomatic uterine leiomyoma: A systematic review. Steroids. 2014; 86: 69 â 78.
dc.identifier.citedreferenceDonnez J, Tatarchuk TF, Bouchard P, et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med. 2012; 366: 409 â 420.
dc.identifier.citedreferenceMurji A, Whitaker L, Chow TL, Sobel ML. Selective progesterone receptor modulators (SPRMs) for uterine fibroids. Cochrane Database Syst Rev. 2017;( 4 ): CD010770.
dc.identifier.citedreferenceLethaby A, Vollenhoven B, Sowter M. Preâ operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids. Cochrane Database Syst Rev. 2001;( 2 ): CD000547.
dc.identifier.citedreferenceArcher DF, Stewart EA, Jain RI, et al. Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: Results from a phase 2a proofâ ofâ concept study. Fertil Steril. 2017; 108: 152 â 160.
dc.identifier.citedreferenceLow MSY, Speedy J, Styles CE, Deâ Regil LM, Pasricha SR. Daily iron supplementation for improving anaemia, iron status and health in menstruating women. Cochrane Database Syst Rev. 2016;( 4 ): CD009747.
dc.identifier.citedreferenceSong H, Lu D, Navaratnam K, Shi G. Aromatase inhibitors for uterine fibroids. Cochrane Database Syst Rev. 2013;( 10 ): CD009505.
dc.identifier.citedreferenceLee BB, Yu SP. Radiofrequency ablation of uterine fibroids: A review. Curr Obstet Gynecol Rep. 2016; 5: 318 â 324.
dc.identifier.citedreferenceGupta JK, Sinha A, Lumsden MA, Hickey M. Uterine artery embolization for symptomatic uterine fibroids. Cochrane Database Syst Rev. 2014;( 12 ): CD005073.
dc.identifier.citedreferenceDe Bruijn AM, Ankum WM, Reekers JA, et al. Uterine artery embolization vs. hysterectomy in the treatment of symptomatic uterine fibroids: 10â year outcomes from the randomized EMMY trial. Am J Obstet Gynecol. 2016; 215: 745.e1 â 745.e12.
dc.identifier.citedreferenceSandberg EM, Tummers FHMP, Cohen SL, van den Haak L, Dekkers OM, Jansen FW. Reintervention risk and quality of life outcomes after uterineâ sparing interventions for fibroids: A systematic review and metaâ analysis. Fertil Steril. 2018; 109: 698 â 707.
dc.identifier.citedreferenceKotani Y, Tobiume T, Fujishima R, et al. Recurrence of uterine myoma after myomectomy: Open myomectomy versus laparoscopic myomectomy. J Obstet Gynaecol Res. 2018; 44: 298 â 302.
dc.identifier.citedreferenceBhave Chittawar P, Franik S, Pouwer AW, Farquhar C. Minimally invasive surgical techniques versus open myomectomy for uterine fibroids. Cochrane Database Syst Rev. 2014;( 10 ): CD004638.
dc.identifier.citedreferencePitter MC, Simmonds C, Seshadriâ Kreaden U, Hubert HB. The impact of different surgical modalities for hysterectomy on satisfaction and patient reported outcomes. J Med Internet Res. 2014; 3: e11.
dc.identifier.citedreferenceHavryliuk Y, Setton R, Carlow JJ, Shaktman BD. Symptomatic fibroid management: Systematic review of the literature. JSLS. 2017; 21: e2017. 00041.
dc.identifier.citedreferenceMunro MG. Endometrial ablation. Best Pract Res Clin Obstet Gynaecol. 2018; 46: 120 â 139.
dc.identifier.citedreferenceStewart EA, Lytle BL, Thomas L, et al. The comparing options for management: patientâ centered results for uterine fibroids (COMPAREâ UF) registry: rationale and design. Am J Obstet Gynecol. 2018; 219: 95.e1 â 95.e10.
dc.identifier.citedreferenceBulun SE. Uterine fibroids. N Engl J Med. 2013; 369: 1344 â 1355.
dc.identifier.citedreferenceStewart EA. Clinical practice. Uterine fibroids. N Engl J Med. 2015; 372: 1646 â 1655.
dc.identifier.citedreferenceMarsh EE, Bulun SE. Steroid hormones and leiomyomas. Obstet Gynecol Clin North Am. 2006; 33: 59 â 67.
dc.identifier.citedreferenceMarsh EE, Ekpo GE, Cardozo ER, Brocks M, Dune T, Cohen LS. Racial differences in fibroid prevalence and ultrasound findings in asymptomatic young women (18â 30 years old): A pilot study. Fertil Steril. 2013; 99: 1951 â 1957.
dc.identifier.citedreferenceBaird DD, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in black and white women: Ultrasound evidence. Am J Obstet Gynecol. 2003; 188: 100 â 107.
dc.identifier.citedreferenceCardozo ER, Clark AD, Banks NK, Henne MB, Stegmann BJ, Segars JH. The estimated annual cost of uterine leiomyomata in the United States. Am J Obstet Gynecol. 2012; 206: 211.
dc.identifier.citedreferenceSoliman AM, Yang H, Du EX, Kelkar SS, Winkel C. The direct and indirect costs of uterine fibroid tumors: A systematic review of the literature between 2000 and 2013. Am J Obstet Gynecol. 2015; 213: 141 â 160.
dc.identifier.citedreferenceMarsh EE, Brocks ME, Ghant MS, Recht HS, Simon M. Prevalence and knowledge of heavy menstrual bleeding among African American women. Int J Gynecol Obstet. 2014; 125: 56 â 59.
dc.identifier.citedreferenceShen Y, Xu Q, Xu J, Ren ML, Cai YL. Environmental exposure and risk of uterine leiomyoma: An epidemiologic survey. Eur Rev Med Pharmacol Sci. 2013; 17: 3249 â 3256.
dc.identifier.citedreferenceSegars JH, Parrott EC, Nagel JD, et al. Proceedings from the third national institutes of health international congress on advances in uterine leiomyoma research: Comprehensive review, conference summary and future recommendations. Hum Reprod Update. 2014; 20: 309 â 333.
dc.identifier.citedreferenceMoravek MB, Yin P, Ono M, et al. Ovarian steroids, stem cells and uterine leiomyoma: Therapeutic implications. Hum Reprod Update. 2014; 21: 1 â 12.
dc.identifier.citedreferenceLaughlinâ Tommaso SK, Stewart EA. Moving toward individualized medicine for uterine leiomyomas. Obstet Gynecol. 2018; 132: 961 â 971.
dc.identifier.citedreferenceLevens ED, Wesley R, Premkumar A, Blocker W, Nieman LK. Magnetic resonance imaging and transvaginal ultrasound for determining fibroid burden: Implications for research and clinical care. Am J Obstet Gynecol. 2009; 200: 537.
dc.identifier.citedreferenceGhant MS, Sengoba KS, Recht H, Cameron KA, Lawson AK, Marsh EE. Beyond the physical: A qualitative assessment of the burden of symptomatic uterine fibroids on women’s emotional and psychosocial health. J Psychosom Res. 2015; 78: 499 â 503.
dc.identifier.citedreferenceMunro MG, Critchley HOD, Broder MS, Fraser IS. FIGO classification system (PALMâ COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age; for the FIGO working group on menstrual disorders. Int J Gynecol Obstet. 2011; 113: 3 â 13.
dc.identifier.citedreferenceAmerican College of Obstetricians and Gynecologists. ACOG practice bulletin. Alternatives to hysterectomy in the management of leiomyomas. Obstet Gynecol. 2008; 112 ( 2 Pt 1 ): 387 â 400.
dc.identifier.citedreferenceDonnez J, Dolmans Mâ M. Uterine fibroids management: From the present to the future. Hum Reprod Update. 2016; 22: 665 â 686.
dc.identifier.citedreferenceSohn GS, Cho S, Kim YM, et al. Current medical treatment of uterine fibroids. Obstet Gynecol Sci. 2018; 61: 192 â 201.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
ijgo13102.pdf
Size:
956.5KB
Format:
PDF
View/Open
Name:
ijgo13102_am.pdf
Size:
294.9KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.